Replies to post #97343 on Biotech Values

[acgood]

Moreover, the recent change in the size of the LibiGel safety trial warrants an extra dose of caution insofar as it might mean an undisclosed change was made to the thresholds and analyses

I'm quite sure they have recently emphasized that there has been no change, that there has always been a large range based on the number of events needed for the (sort of) non-inferiority test of CV events. But obviously concern remains over the extended timeline (doubly concerning because it gives them more time to mess around with the remains of CEGE)